RecruitingPhase 4NCT06195241
Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
Studying Hemifacial spasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Montefiore Medical Center
- Principal Investigator
- Anne Barmettler, MDMontefiore Medical Center/Albert Einstein College of Medicine
- Intervention
- DaxibotulinumtoxinA(drug)
- Enrollment
- 40 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Montefiore Medical Center, The Bronx, New York, United States
Collaborators
Revance Therapeutics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06195241 on ClinicalTrials.gov